Search

Amgen Inc

Chiusa

SettoreSettore sanitario

382.31 -2.17

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

381.42

Massimo

391.28

Metriche Chiave

By Trading Economics

Entrata

-3.6B

-1.8B

Vendite

1.4B

10B

P/E

Media del settore

27.174

56.597

EPS

6.29

Rendimento da dividendi

2.21

Margine di Profitto

-18.092

Dipendenti

31,500

EBITDA

-416M

3.4B

Dividendi

By Acuity

Rendimento da dividendi

Media del settore

2.21%

2.18%

Utili prossimi

3 nov 2026

Prossima data del Dividendo

11 set 2026

Prossima data del' Ex Dividendo

20 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

32B

236B

Apertura precedente

384.48

Chiusura precedente

382.31

Notizie sul Sentiment di mercato

By Acuity

51%

49%

269 / 339 Classifica in Healthcare

Amgen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2026, 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

4 set 2026, 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

3 set 2026, 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2 set 2026, 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

1 set 2026, 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

31 ago 2026, 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

28 ago 2026, 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

27 ago 2026, 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

26 ago 2026, 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

25 ago 2026, 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

24 ago 2026, 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

21 ago 2026, 20:06 UTC

Event

Amgen Inc. went ex-dividend today, distributing $2.52 per share, as shares trade higher since Thursday's close amid a strong broader market.

20 ago 2026, 23:21 UTC

Amgen Inc. shares are lower in after-market trading, with no specific news identified. Rising U.S. Treasury yields contribute to broader market pressure.

19 ago 2026, 22:56 UTC

Amgen Inc. shares declined slightly in after-hours trading, reflecting a minor decrease since Wednesday's close. The stock remains well above its 20-day moving average.

18 ago 2026, 23:26 UTC

Amgen Inc shares are higher during after-market hours, maintaining a strong position above its 20-day moving average despite broader market pressures.

17 ago 2026, 22:01 UTC

Amgen Inc shares are trading lower in after-market hours. Broader market volatility, influenced by rising crude oil prices, may be affecting investor sentiment.

14 ago 2026, 19:46 UTC

News

Amgen shares are lower today despite Barclays raising the price target to $380, influenced by a decline in U.S. retail sales for July.

13 ago 2026, 20:06 UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

12 ago 2026, 19:56 UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

11 ago 2026, 19:41 UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

7 ago 2026, 19:22 UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

6 ago 2026, 19:56 UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

5 ago 2026, 19:52 UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

4 ago 2026, 23:02 UTC

Social Media
News

Amgen reported strong Q2 results but shares are lower in after-market hours amid rising expense forecasts and the discontinuation of obesity candidate AMG 513.

3 ago 2026, 23:01 UTC

Amgen Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

31 lug 2026, 20:07 UTC

News

Amgen's Board declared a quarterly dividend of $2.52 per share, while shares are trading lower amid rising Treasury yields and inflation concerns.

30 lug 2026, 21:32 UTC

News

Amgen Inc announced a quarterly dividend of $2.52 per share, but shares are lower in after-market trading following mixed tech sector earnings.

29 lug 2026, 23:26 UTC

Amgen Inc. shares traded roughly flat after-market, remaining above the 20-day moving average amid broader market volatility following the Federal Reserve's interest rate decision.

28 lug 2026, 20:02 UTC

Social Media

Amgen Inc. shares are advancing, reaching an all-time high following the acquisition of Horizon, which enhances its focus on rare diseases and strategic growth areas.

27 lug 2026, 23:22 UTC

Amgen Inc shares are higher in after-market hours, reaching a peak late in the session. Broader market sentiment remains positive amid reduced oil supply concerns.

Confronto tra pari

Modifica del prezzo

Amgen Inc Previsione

Consenso sulla valutazione

By TipRanks

Da acquistare moderatamente

24 ratings

9

Acquista

13

Mantieni

2

Vendi

Sentiment

By Acuity

269 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat